{
    "nctId": "NCT02392611",
    "briefTitle": "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer",
    "officialTitle": "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Solid Tumors and Lymphomas",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Number of Participants Experiencing Dose Limiting Toxicities (DLTs)",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Group 1: Histologically or cytologically confirmed advanced malignant solid tumor or lymphoma (any subtype) that is refractory to or intolerant of standard therapy or for which no standard therapy is available\n* Group 2: Post-menopausal women with advanced stage estrogen receptor positive breast cancer who are candidates for exemestane or fulvestrant\n* Group 3: Individuals with lymphoma are limited to diffuse large B-cell lymphoma and peripheral T-cell lymphoma that are refractory to or intolerant of standard therapy or for which no standard therapy is available\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 1\n* Adequate organ function defined as follows:\n\n  * Hematologic: Platelets \u2265 100 x 10\\^9/L; Hemoglobin \u2265 9.0 g/ dL; Absolute neutrophil count (ANC) \u2265 1.5 x 10\\^9/L (without platelet transfusion or any growth factors within previous 7 days of the hematologic laboratory values obtained at screening visit). Participants in the Group 3 lymphoma expansion may be enrolled with an ANC of \u2265 1.0 x 10\\^9 /L; Platelets \u2265 75 x 10\\^9 /L.\n  * Hepatic: Aspartate transaminase (AST) / Alanine transaminase (ALT) \u2264 2.5 x upper limit of normal (ULN) (if liver metastases are present, \u2264 5 x ULN); Total or conjugated bilirubin \u2264 1.5 x ULN\n  * Renal: Serum creatinine \u2264 1.5 x ULN or creatinine clearance (CrCl) \u2265 60 ml/min as calculated by the cockcroft-gault method\n* Coagulation: International Normalized Ratio (INR) \u2264 1.2\n\nKey Exclusion Criteria:\n\n* Known brain metastasis or leptomeningeal disease\n* Myocardial infarction, symptomatic congestive heart failure (New York Heart Association Classification \\> Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of study Day 1\n* Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (ie, larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days of first dose of study drug\n* History of long QT syndrome or whose corrected QT interval (QTc) measured (Fridericia method) at screening is prolonged (\\> 450 ms for males and \\> 470 ms for females). Individuals who screen-fail due to this criterion are not eligible to be re-screened\n* Clinically significant bleeding within 28 days of study Day 1\n* Known human immunodeficiency virus (HIV) infection\n* Hepatitis B surface antigen positive\n* Hepatitis C virus (HCV) antibody positive\n* No active anticoagulation within 7 days of study Day 1; including acetylsalicylic acid, low molecular weight heparin, or warfarin.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}